Last Updated 8 December 2015
The hepatitis C virus (HCV) therapy market is undergoing unprecedented growth. Commercial opportunity is driven by a large prevalent population and historically high unmet medical need due to the suboptimal efficacy and tolerability of interferon-based therapies. Between 2013 and 2015, several direct-acting antivirals (DAAs) and DAA combinations, including simeprevir (Janssen’s Olysio, Medivir’s Sovriad), sofosbuvir (Gilead’s Sovaldi), sofosbuvir/ledipasvir (Gilead’s Harvoni), ombitasvir/paritaprevir/ritonavir plus dasabuvir (AbbVie’s Viekira Pak), and daclatasvir (Bristol-Myers Squibb’s Daklinza), have launched in the G7 for both treatment-naive and -experienced HCV patients. Despite these agents’ high prices, they have become a new standard of care.
Questions Answered in This Report:
- Drug-treatment rates for genotype-1 HCV patients have substantially increased in response to the availability of highly effective interferon-free HCV regimens. What do experts think about currently available therapies for HCV? How are recently launched interferon-free regimens used in medical practice today?
- HCV therapies in late-stage development have the potential to provide pangenotypic efficacy, including efficacy in genotype-3 patients, a patient population still in need of effective therapies. Which currently available and emerging, all-oral, interferon-free therapies are poised for commercial success? How will emerging therapies be differentiated from current DAAs? What patient subgroups do physicians believe are still underserved by current agents?
- Strategic negotiations between marketers and payers have led to a dramatic increase in drug-treatment and HCV cure rates. How will the population of patients eligible for treatment and the drug-treated population change over the next ten years, particularly given the availability of more-effective and -tolerable therapies? What will be the key market drivers and constraints over the next decade?
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 26 country-specific interviews with thought leaders in HCV treatment.
Epidemiology: Seroprevalence of HCV, prevalence of HCV viremia, and incidence of HCV viremia.
Population segments in market forecast: Treatment-naive genotype 1, 4, 5, and 6; treatment-naive genotype 2; treatment-naive genotype 3; treatment-experienced genotype 1, 4, 5, and 6; treatment-experienced genotype 2; treatment-experienced genotype 3.
Emerging therapies: Phase II: 10 drugs; Phase III: 3 drugs; preregistration: 1 drug; registered: 14 drugs.
Kristin Dorfman, M.P.H., M.S.